Foghorn Therapeutics is developing therapies based on a system that directs which genes our cells express,
Foghorn Therapeutics has raised $50.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in January 2026.
Foghorn Therapeutics's investors include Casdin Capital, Invus, Deerfield Management, Flagship Pioneering, Irving Investors.
Foghorn Therapeutics is headquartered in Cambridge, United States.
Foghorn Therapeutics is developing therapies based on a system that directs which genes our cells express,
Foghorn Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Foghorn Therapeutics — Funding & Investors." VCBacked, January 9, 2026, https://www.vcbacked.co/company/foghorn-therapeutics. Accessed August 15, 2026.
VCBacked. (2026). Foghorn Therapeutics — Funding & Investors. Retrieved August 15, 2026, from https://www.vcbacked.co/company/foghorn-therapeutics
{{cite web |title=Foghorn Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/foghorn-therapeutics |website=VCBacked |access-date=August 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated